
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. has demonstrated steady growth in the volume of EsoGuard tests, with Q3 2025 processing 2,841 tests, a 2% increase year-over-year, and projections indicate revenue growth will align closely with this increasing test volume as Medicare coverage expands. The company is enhancing its coverage from various payers, including private insurers and cash-pay plans, which is expected to accelerate revenue growth further in the latter half of 2025. Additionally, a recent positive meeting with the MolDX and CAC points to an anticipated favorable coverage decision, suggesting improved market access for the company's diagnostic offerings.
Bears say
Lucid Diagnostics Inc. reported a pro forma net loss of $10.3 million in 3Q25, which was higher than the anticipated loss of $6 million, reflecting ongoing challenges in achieving profitability. The company also underperformed in revenue, falling short of consensus expectations, highlighting potential issues with the market adoption of its products, particularly EsoGuard. Additionally, multiple risks, including dependency on insurance reimbursement and competition, further exacerbate the negative outlook on the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares